Pharma company Lupin is all set to announce its Q2 results on Wednesday. Here's what to expect:
The company is expected to report around 10 percent growth on a year-on-year (YoY) basis.
The profit is likely to grow by more than 20 percent.
What will drive growth this time would be the US business.
In terms of the operational improvement, in the last quarter, the EBITDA was up around 63 percent. The company is expected to continue in terms of the trend in margins on account of cost control.